GlobeNewswire Inc.··NaObesity Biotech Kailera Prices IPO at $16/Share, Eyes $625M Raise
Clinical-stage biotech Kailera prices IPO at $16/share, raising $625M. Company debuts on Nasdaq ($KLRA) April 17 with positive Phase 2 obesity drug data.
JHPCYIPObiotechnology